The Hong Kong-listed medical aesthetic firm, which specializes in energy-based devices and injectables, intends to execute the buyback under its existing mandate. Depending on future capital needs, the company may either cancel the acquired shares or retain them as treasury stock. Co-CEO and CFO Jiahong Li stated that the decision reflects a comprehensive assessment of the company’s current financial position and market performance.
In section Releases
Sisram Medical Targets 1% Share Buyback to Boost Investor Value
Sisram Medical Ltd is moving to repurchase up to 1% of its issued shares from the open market, signaling board-level confidence in the wellness group’s long-term trajectory. The move follows a period of steady financial gains, with the company aiming to balance capital management with ongoing strategic growth initiatives.
Sisram’s recent financial results underscore a period of expansion, with first-half 2026 revenue reaching $171.4 million—a 3.6% increase year-on-year. International markets outside North America proved particularly resilient, growing 16.7% to $127 million. The injectables segment has emerged as a significant growth engine, jumping 54.2% to $22.2 million. As the company continues to scale its operations across its three strategic hubs in Israel, the United States, and China, management emphasized that the repurchase program remains a disciplined effort to share growth benefits with shareholders while maintaining flexibility for further business development.
Comments (0)
No comments yet. Be the first!